Dixie-Lee Esseltine

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

Xing‐Ding Zhang, Veerabhadran Baladandayuthapani, Heather Lin et al. · Cancer Cell · 2016 · 103 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

David I. Lichter, Hadi Danaee, Michael D. Pickard et al. · Blood · 2012 · 71 citations · Full text

Medicine, Molecular Biology, Oncology +13

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Patricia LoRusso, Karthik Venkatakrishnan, Ramesh K. Ramanathan et al. · Clinical Cancer Research · 2012 · 71 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Neeraj Gupta, Yeow Tee Goh, Chang‐Ki Min et al. · Journal of Hematology & Oncology · 2015 · 39 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

Paul G. Richardson, Sundar Jagannath, Noopur Raje et al. · Blood · 2007 · 30 citations

Medicine, Hematology, Pharmacotherapy +14